Dr. Robert McNally graduated with a Ph.D. in Biomedical Engineering from the University of Pennsylvania and has over 28 years of experience in academic and corporate clinical investigations, management, research, business, quality and regulatory affairs.
Dr. McNally is the President and CEO of GeoVax. Previously, he served as President as well as VP of Quality Assurance of Cell Dynamics, a company he co-founded. Cell Dynamics worked with organ and tissue procurement organizations for the recovery of human tissue processing these tissues into cellular components necessary for research and development, pharmaceuticals and cell therapy. In 1984, Dr. McNally co-founded CryoLife, Inc., a company specializing in the cryopreservation of human tissue for transplant. During his 14 year association with CryoLife, it grew to $50M in revenue, became a public company on NYSE and received world recognition as a leader in transplant technology.
He is a Fellow of the American Institute of Medical and Biological Engineers, serves on the board of the Petit Institute for Tissue Engineering at Georgia Tech and is Past Chairman of the Georgia Biomedical Partnership and recipient of its 2005 Biomedical Industry Growth Award.
Mr. Reynolds is an experienced financial manager and business adviser with an in depth knowledge of SEC reporting and compliance. Having spent the past seventeen years working in both high growth and restructuring environments, Mr. Reynolds has worked with a number of start-up companies designing financial systems and procedures from the ground up.
Most recently, Mr. Reynolds served as the Chief Financial Officer, Company Secretary, and Controller at Cytrx Corporation, a publicly held biomedical firm based originally in Atlanta Georgia. He also served as the CFO and Controller for three of the company’s wholly owned subsidiaries. During his tenure at Cytrx, he maintained relationships with the Board of Directors, Investors, NASDAQ Representatives, Management Team and Staff.
Mr. Reynolds is a Certified Public Accountant and earned a Masters Degree in Accounting from the University of Georgia.
Dr. Robinson is the developer of GeoVax' HIV-1 AIDS vaccine technology. One of the world's leaders in AIDS vaccine research, she currently serves as Chief Scientific Officer for GeoVax. Previously, she was Chief of the Division of Microbiology and Immunology at the Yerkes National Primate Research Center and the Asa Griggs Candler Professor of Microbiology and Immunology at Emory University.
Dr. Robinson has published extensively on HIV-AIDS vaccine research as well as viral-induced cancers. Her pioneering studies on the development of DNA vaccines demonstrated not only that DNA could raise protective immunity for viral infections, but also identified methods of DNA delivery that could be used to control the type of immune responses raised by DNA vaccines.
Her early work with HIV vaccines demonstrated that DNA alone would not be sufficient to raise protective immunity for HIV. She then combined DNA with protein boosters or live viral-vectored boosters to show that the most effective control was through a combination of DNA prime and viral-vectored boosters. Her most recent work has developed single multiprotein expressing DNA, and working with the NIAID-NIH, a single poxvirus vector (MVA) has been developed to be used for priming and boosting. It is these vaccines that GeoVax has licensed for commercial development.
Dr. Robinson has published extensively on HIV-AIDS vaccine research with more than 130 referred scientific journal publications, 45 monograph reviews and 6 book chapters authored. She has consulted for the US National Institutes of Health, the US Food and Drug Administration, the Bill and Melinda Gates Foundation, and the World Health Organization.
Dr. Robinson received her B.A. from Swarthmore College and took her PhD in Microbiology from Massachusetts Institute of Technology. She has been elected to the American Academy of Microbiology.